Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA for prevention of colorectal cancer recurrence after liver metastasis resection
2016-000628-24Phase 3Unknown
- Sponsor
- University of Leeds
- Start
- May 2018
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Icosapent ethyl with Placebo (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
omega-3-acid triglycerides
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2016-000628-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000628-24.